NEW YORK (GenomeWeb News) – Shares of CombiMatrix rose as much as 25 percent today after the company said that it expects to report record volumes of prenatal testing for the first quarter.

The Irvine, Calif.-based firm said today that for the three months ended March 31, billable prenatal tests were up 124 percent year over year in preliminary results. Investors responded by driving shares up as high as $4.62, up from Wednesday's closing price of $3.46.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The ancestors of the Arizona bark scorpion and other scorpions and spiders underwent whole-genome duplication, KJZZ reports.

A cryptographic approach could help researchers keep genomic data private while researchers analyze it, Scientific American reports.

Andy Page, the former president of 23andMe, has joined a diabetes-management startup, according to CNBC.

In Cell this week: regulatory changes in pancreatic cancer, metabolic shifts in Alzheimer's disease, and more.